Shares of Axsome Therapeutics Inc. (AXSM) rose more than 6% on Monday, following positive results from its phase II trial of AXS-05 for smoking cessation treatment. Let's take a look at some more biotech companies awaiting phase II or phase III clinical trial results this quarter.
from RTT - Biotech http://bit.ly/2XjPq9h
via IFTTT
No comments:
Post a Comment